latanoprost; netarsudil dimesylate - Profile

What are the generic drug sources for latanoprost; netarsudil dimesylate and what is the scope of freedom to operate?

Latanoprost; netarsudil dimesylate is the generic ingredient in one branded drug marketed by Alcon Labs Inc and is included in one NDA. There are seventeen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Latanoprost; netarsudil dimesylate has sixty-eight patent family members in fourteen countries.

Summary for latanoprost; netarsudil dimesylate

International Patents:	68
US Patents:	17
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for latanoprost; netarsudil dimesylate

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for latanoprost; netarsudil dimesylate

Constraining patent/regulatory exclusivity:

9,415,043

Dosage:

SOLUTION/DROPS;OPHTHALMIC

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for LATANOPROST; NETARSUDIL DIMESYLATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ROCKLATAN	Ophthalmic Solution	latanoprost; netarsudil dimesylate	0.005%/0.02%	208259	2	2021-12-20

US Patents and Regulatory Information for latanoprost; netarsudil dimesylate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alcon Labs Inc	ROCKLATAN	latanoprost; netarsudil dimesylate	SOLUTION/DROPS;OPHTHALMIC	208259-001	Mar 12, 2019		RX	Yes	Yes	9,993,470		Y	Y
Alcon Labs Inc	ROCKLATAN	latanoprost; netarsudil dimesylate	SOLUTION/DROPS;OPHTHALMIC	208259-001	Mar 12, 2019		RX	Yes	Yes	9,931,336		Y	Y
Alcon Labs Inc	ROCKLATAN	latanoprost; netarsudil dimesylate	SOLUTION/DROPS;OPHTHALMIC	208259-001	Mar 12, 2019		RX	Yes	Yes	10,174,017		Y	Y
Alcon Labs Inc	ROCKLATAN	latanoprost; netarsudil dimesylate	SOLUTION/DROPS;OPHTHALMIC	208259-001	Mar 12, 2019		RX	Yes	Yes	9,096,569		Y	Y
Alcon Labs Inc	ROCKLATAN	latanoprost; netarsudil dimesylate	SOLUTION/DROPS;OPHTHALMIC	208259-001	Mar 12, 2019		RX	Yes	Yes	8,450,344		Y	Y

International Patents for latanoprost; netarsudil dimesylate

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2010011853
Australia	2014228790	Combination therapy
Canada	2731869	COMPOSES AMIDES BETA ET GAMMA-AMINO ISOQUINOLINE ET COMPOSES BENZAMIDE SUBSTITUE (BETA-AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUNDS AND SUBSTITUTED BENZAMIDE COMPOUNDS)
European Patent Office	2424857	INHIBITEURS À DOUBLE ACTION ET LEURS PROCÉDÉS D'UTILISATION (DUAL-ACTION INHIBITORS AND METHODS OF USING SAME)
Australia	2021204320

Supplementary Protection Certificates for latanoprost; netarsudil dimesylate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3461484	132021000000068	Italy		PRODUCT NAME: COMBINAZIONE DI LATANOPROST E NETARSUDIL(ROCLANDA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1502, 20210108
3461484	C202130024	Spain		PRODUCT NAME: NETARSUDIL O UN ENANTIOMERO, DIASTEREIOISOMERO, SAL O SALVADO DEL MISMO EN COMBINACION CON LATANOPROST O UNA SAL DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/20/1502; DATE OF AUTHORISATION: 20210107; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1502; DATE OF FIRST AUTHORISATION IN EEA: 20210107
3053913	2020C/510	Belgium		PRODUCT NAME: RHOKIINSA - NETARSUDIL; AUTHORISATION NUMBER AND DATE: EU/1/19/1400 20191121
3053913	SPC/GB20/019	United Kingdom		PRODUCT NAME: NETARSUDIL; REGISTERED: UK EU/1/19/1400(NI) 20191121; UK PLGB 16058/003 20191121
3053913	20C1017	France		PRODUCT NAME: NETARSUDIL, OU ENANTIOMERE, DIASTEREOMERE, SEL OU SOLVATE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/19/1400 20191121

Investment Scenario and Fundamentals Analysis for Latanoprost and Netarsudil Dimesylate

Last updated: February 20, 2026

What are the current market dynamics for latanoprost and netarsudil dimesylate?

Latanoprost, a prostaglandin analog, dominates the glaucoma treatment market with an estimated annual revenue of $1.8 billion globally (2022). It is approved for first-line use, with patents expiring in 2029, increasing generic competition expected from 2024 onward. Key players include Allergan (AbbVie), Sandoz, and other generics manufacturers.

Netarsudil dimesylate, marketed as Rhopressa and Rhokilsa, entered the glaucoma segment in 2017 and 2018 respectively. Its global revenue is approximately $250 million (2022). It presents an alternative mechanism of action as a Rho kinase inhibitor, targeting intraocular pressure (IOP) reduction more effectively in patients resistant to prostaglandins.

Market Share and Competitive Landscape

Drug	Market Share (2022)	Patent Status	Key Competitors
Latanoprost	60%	Patent until 2029	Bimatoprost, Travoprost (generics)
Netarsudil	10%	Patent until 2032	Other Rho kinase inhibitors (investigational)

The dominance of latanoprost stems from early market entry, proven efficacy, and consumer familiarity. However, generic entries threaten its market share. Netarsudil's smaller market share reflects its newer status, with growth potential in treatment-resistant cases.

What are the regulatory and patent considerations?

Latanoprost's patent expiry opens avenues for generics, leading to price erosion. The approximate patent protection lasts until 2029, after which generic manufacturers can launch equivalents, increasing price competition. Its biosimilars or alternative formulations could enter as early as 2024 if patent challenges succeed.

Netarsudil's patent protection extends to 2032, with a formulation patent expiring in 2028. The drug has secured approvals in major regions, including the US, EU, and Japan, with a focus on formulations that extend patent life and new indications.

What are the R&D and pipeline prospects?

Latanoprost's primary challenge is market saturation, with incremental improvements such as combination formulations and preservative-free options. These modifications do not significantly alter the fundamental patent landscape.

Netarsudil's pipeline includes combinations with latanoprost and other agents, aiming to enhance efficacy. Phase III trials are ongoing for combination therapies, with potential launches between 2023 and 2025. The drug’s unique mechanism offers differentiation opportunities.

How does the pricing landscape influence investment?

Pricing for latanoprost ranges between $50–$70 per month in the US for branded versions, with generics priced below $30. The price erosion post-patent expiry will pressure margins for originators.

Netarsudil’s pricing is approximately $180 per month in the US. As a newer drug, it benefits from higher pricing. Future biosimilar or generic entrants could halve the price, impacting revenue forecasts.

What are the risks and opportunities?

Risks:

• Patent cliffs for latanoprost may compress margins.
• The slow adoption of netarsudil due to physician inertia and competition.
• Potential regulatory delays or label restrictions affecting netarsudil.

Opportunities:

• Growing prevalence of glaucoma and ocular hypertension, driven by aging populations.
• Expansion into combination therapies and new indications.
• Development of new delivery systems, such as sustained-release implants, to extend market exclusivity.

What are the key financial considerations?

Indicator	Latanoprost	Netarsudil
Estimated 2022 Revenue	$1.8 billion	$250 million
Patent Expiry	2029	2032
Expected CAGR (2022–2027)	3%	5%

Revenue growth for latanoprost will slow as generics enter, while netarsudil’s growth depends on pipeline success and market penetration.

Conclusion

Latanoprost faces imminent generic competition, creating downward pressure on revenues but remains dominant for now. Investment in companies holding extensive patent portfolios or developing advanced formulations is advisable. Netarsudil presents growth prospects owing to its innovative mechanism and ongoing pipeline developments, though challenges in adoption and competitive pressures persist.

Key Takeaways

• Latanoprost is the leading glaucoma drug with significant revenue but near patent expiry; prospects depend on generic competition.
• Netarsudil's market share is growing through efficacy in resistant cases, backed by a solid pipeline and patent protection until 2032.
• Pricing erosion post-patent expiry and the speed of market adoption are critical valuation factors.
• Pipeline developments, especially combination therapies, are potential drivers for future growth.
• The aging population will sustain long-term demand for both drugs, benefitting companies with diversified glaucoma portfolios.

FAQs

1. When will generic latanoprost become available?
   After patent expiration in 2029, with generics likely to launch in 2024–2029, depending on patent challenges and market strategies.

2. Can netarsudil replace latanoprost as frontline therapy?
   Currently, no. Netarsudil is mainly used for patients resistant to prostaglandins or as part of combination therapies.

3. What is the key differentiation of netarsudil?
   Its mechanism as a Rho kinase inhibitor targets aqueous humor outflow through the trabecular meshwork, providing efficacy in resistant cases.

4. What regulatory delays could impact netarsudil's growth?
   Adverse trial outcomes, label restrictions, or manufacturing issues could delay approvals for new indications or formulations.

5. How do pipeline developments affect investment risk?
   Successful development of combination therapies or new delivery methods can extend patent life and boost revenue, reducing investment risk. Conversely, failures could diminish growth prospects.

---

References

[1] IMS Health (2022). Global ophthalmic drugs market analysis.
[2] FDA (2022). Approval summaries for Rhopressa and Rhokilsa.
[3] Pharma Intelligence (2022). Glaucoma therapeutics outlook and patent landscape.